Indian Patent Office rejects patent for Sofosbuvir.
Indian Patent Office has rejected a patent application for Sofosbuvir which was discovered by Pharmasset and developed by Gilead Sciences. Sofosbuvir is used against Hepatitis C. The patent application which was filed by Gilead covered the drug product which has been granted in several territories including US.
The price of patented medicines has always been a concern for the Indian healthcare industry. With this decision, we can be rest assured that patients with Hepatitis C would have access to affordable treatment options.
It is however worth noting that Indian companies like Cipla, Zydus, Hetero, Ranbaxy and others had entered into license agreements with Gilead to sell their product in India. Gilead had also planned to launch its own drug Sovaldi at the cost of 300USD per bottle.
The price of patented medicines has always been a concern for the Indian healthcare industry. With this decision, we can be rest assured that patients with Hepatitis C would have access to affordable treatment options.
It is however worth noting that Indian companies like Cipla, Zydus, Hetero, Ranbaxy and others had entered into license agreements with Gilead to sell their product in India. Gilead had also planned to launch its own drug Sovaldi at the cost of 300USD per bottle.
Comments
Post a Comment